Roche, Eli Lilly, Novo, gene therapy, Hansoh: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. ARPA-H has unveiled a $160 million effort to speed bespoke gene-editing therapies for rare diseases into the clinic. Meanwhile, Roche has abandoned two Huntington’s gene-silencing drugs after disappointing data, and drugmakers have stepped in to…
